Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial
Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today ...
Medicenna To Present At Jones Healthcare And Technology Innovation Conference
The Jones Healthcare and Technology Innovation Conference is recognized for bringing together a select group of innovative companies and institutional investors for a two-day event. The event will be ...
ESTEVE Signs A Licensing Agreement For A Severe Primary Insulin-Like Growth Factor 1 Deficiency Treatment
It is a biologic product used to treat children and adolescents from 2 to 18 years-old who suffer from severe primary insulin-like growth ...
JD Supra10h
A Look Ahead in Life Sciences: What We Are Tracking in the Second Quarter of 2025 and Beyond
As the life sciences, medtech, and diagnostic industries continue to expand and grow increasingly complex, so does the legal, regulatory, ...
gut.bmj5h
British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis
14 Centre for Liver and Gastroenterology research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK 15 NIHR Biomedical Research Centre, University of Birmingham and ...